Many companies have foreshadowed deals to come during earnings calls in recent days. The return of M&A would be a welcome ...

Recent developments in health highlight key agreements between countries, drug approvals, corporate revenue growth, and ...

Germany's Merck KGaA has struck a deal to buy U.S. biotech company SpringWorks Therapeutics for an equity value of $3.9 ...

Germany’s Merck KGaA has agreed to acquire U.S. biotech SpringWorks Therapeutics for $3.9 billion. The acquisition, aimed at ...

The killing of a veteran Filipino journalist in his home was a "heinous act" that was being investigated by police, the Philippines' Presidential Task Force on Media Security said on Wednesday. Juan ...

Barely a year after the U.S. FDA shackled Abeona Therapeutics Inc.’s cell-based gene therapy with a complete response letter, the agency has approved it for treating a rare and genetic skin disease.

Merck KGaA said the deal will grow its U.S. presence and expand the reach of SpringWorks’ drugs, including one approved in February.

With April 29 being Day 100 for U.S. President Donald Trump, his staff observed the day by touting the achievements of the administration’s first 100 days in office, especially new commitments made by ...